April 19, 2011

Developments in Compulsory Licensing

Thailand: IP Developments, Tilleke & Gibbins Client Newsletter

A little more than a year ago, Thailand’s Ministry of Public Health, acting on behalf of a post-coup military-appointed admin­istration, decided to issue the first set of compulsory licenses on three patented drugs. The three drugs were Merck’s antiretroviral efavirenz (Stocrin®), Abbott Laborato­ries’ antiretro­viral lopinavir/ritonavir (Kaletra®) and sanofi-aventis’ heart disease drug clopi­dogrel (Plavix®). This article examines the developments that have occurred since the compulsory licenses were announced and explains the procedural issues involved in the current debate about their legitimacy.

AUTHORS
Edward Kelly
Email

RELATED INSIGHTS​